{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:34:48Z","timestamp":1791232488910,"version":"4.1.0"},"reference-count":19,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2002,3,1]]},"abstract":"<jats:p>Mutations of c-KIT causing spontaneous activation of the KIT receptor kinase are associated with sporadic adult human mastocytosis (SAHM) and with human gastrointestinal stromal tumors. We have classified KIT-activating mutations as either \u201cenzymatic site\u201d type (EST) mutations, affecting the structure of the catalytic portion of the kinase, or as \u201cregulatory\u201d type (RT) mutations, affecting regulation of an otherwise normal catalytic site. Using COS cells expressing wild-type or mutant KIT, 2 compounds, STI571 and SU9529, inhibited wild-type and RT mutant KIT at 0.1 to 1 \u03bcM but did not significantly inhibit the Asp816Val EST mutant associated with SAHM, even at 10 \u03bcM. Using 2 subclones of the HMC1 mast cell line, which both express KIT with an identical RT mutation but which differ in that one also expresses the Asp816Val EST mutation, both compounds inhibited the RT mutant KIT, thereby suppressing proliferation and producing apoptosis in the RT mutant-only cell line. Neither compound suppressed activation of Asp816Val EST mutant KIT, and neither produced apoptosis or significantly suppressed proliferation of the cell line expressing the Asp816Val mutation. These studies suggest that currently available KIT inhibitors may be useful in treating neoplastic cells expressing KIT activated by its natural ligand or by RT activating mutations such as gastrointestinal stromal tumors but that neither compound is likely to be effective against SAHM. Furthermore, these results help establish a general paradigm whereby classification of mutations affecting oncogenic enzymes as RT or EST may be useful in predicting tumor sensitivity or resistance to inhibitory drugs.<\/jats:p>","DOI":"10.1182\/blood.v99.5.1741","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T12:46:40Z","timestamp":1027774000000},"page":"1741-1744","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":366,"title":["The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations"],"prefix":"10.1182","volume":"99","author":[{"given":"Yongsheng","family":"Ma","sequence":"first","affiliation":[{"name":"From the Departments of Dermatology and Pathology, College of Physicians and Surgeons, Columbia University, New York, NY; Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; Novartis, Basel, Switzerland; Department of Allergic Diseases, Mayo Clinic, Rochester, MN; and SUGEN, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Zeng","sequence":"additional","affiliation":[{"name":"From the Departments of Dermatology and Pathology, College of Physicians and Surgeons, Columbia University, New York, NY; Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; Novartis, Basel, Switzerland; Department of Allergic Diseases, Mayo Clinic, Rochester, MN; and SUGEN, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean D.","family":"Metcalfe","sequence":"additional","affiliation":[{"name":"From the Departments of Dermatology and Pathology, College of Physicians and Surgeons, Columbia University, New York, NY; Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; Novartis, Basel, Switzerland; Department of Allergic Diseases, Mayo Clinic, Rochester, MN; and SUGEN, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Akin","sequence":"additional","affiliation":[{"name":"From the Departments of Dermatology and Pathology, College of Physicians and Surgeons, Columbia University, New York, NY; Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; Novartis, Basel, Switzerland; Department of Allergic Diseases, Mayo Clinic, Rochester, MN; and SUGEN, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasa","family":"Dimitrijevic","sequence":"additional","affiliation":[{"name":"From the Departments of Dermatology and Pathology, College of Physicians and Surgeons, Columbia University, New York, NY; Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; Novartis, Basel, Switzerland; Department of Allergic Diseases, Mayo Clinic, Rochester, MN; and SUGEN, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph H.","family":"Butterfield","sequence":"additional","affiliation":[{"name":"From the Departments of Dermatology and Pathology, College of Physicians and Surgeons, Columbia University, New York, NY; Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; Novartis, Basel, Switzerland; Department of Allergic Diseases, Mayo Clinic, Rochester, MN; and SUGEN, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"McMahon","sequence":"additional","affiliation":[{"name":"From the Departments of Dermatology and Pathology, College of Physicians and Surgeons, Columbia University, New York, NY; Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; Novartis, Basel, Switzerland; Department of Allergic Diseases, Mayo Clinic, Rochester, MN; and SUGEN, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Jack","family":"Longley","sequence":"additional","affiliation":[{"name":"From the Departments of Dermatology and Pathology, College of Physicians and Surgeons, Columbia University, New York, NY; Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; Novartis, Basel, Switzerland; Department of Allergic Diseases, Mayo Clinic, Rochester, MN; and SUGEN, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021219322999800_B1","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1002\/j.1460-2075.1987.tb02655.x","article-title":"Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand.","volume":"6","author":"Yarden","year":"1987","journal-title":"EMBO J."},{"key":"2020021219322999800_B2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0092-8674(90)90301-T","article-title":"Primary structure and functional expression of rat and human stem cell factor DNAs.","volume":"63","author":"Martin","year":"1990","journal-title":"Cell."},{"key":"2020021219322999800_B3","first-page":"1","article-title":"The kit ligand, stem cell factor.","volume":"55","author":"Galli","year":"1994","journal-title":"Adv Immunol."},{"key":"2020021219322999800_B4","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1172\/JCI116761","article-title":"Identification of mutations in the coding sequence of the proto-oncogene c-KIT in a human mast cell leukemia cell line causing ligand-independent activation of c-KIT product.","volume":"92","author":"Furitsu","year":"1993","journal-title":"J Clin Invest."},{"key":"2020021219322999800_B5","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder.","volume":"92","author":"Nagata","year":"1995","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2020021219322999800_B6","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/ng0396-312","article-title":"Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm.","volume":"12","author":"Longley","year":"1996","journal-title":"Nat Genet."},{"key":"2020021219322999800_B7","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1073\/pnas.96.4.1609","article-title":"Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis.","volume":"96","author":"Longley","year":"1999","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2020021219322999800_B8","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1182\/blood.V83.9.2619.2619","article-title":"Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line p815 generated by a point mutation.","volume":"83","author":"Tsujimura","year":"1994","journal-title":"Blood."},{"key":"2020021219322999800_B9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1046\/j.1523-1747.1999.00488.x","article-title":"Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms.","volume":"112","author":"Ma","year":"1999","journal-title":"J Invest Dermatol."},{"key":"2020021219322999800_B10","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1046\/j.1523-1747.2000.00888.x","article-title":"Indolinone derivatives inhibit constitutively activated KIT mutants and kill neoplastic mast cells.","volume":"114","author":"Ma","year":"2000","journal-title":"J Invest Dermatol."},{"key":"2020021219322999800_B11","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0145-2126(01)00028-5","article-title":"Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy.","volume":"25","author":"Longley","year":"2001","journal-title":"Leuk Res."},{"key":"2020021219322999800_B12","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1126\/science.279.5350.577","article-title":"Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.","volume":"279","author":"Hirota","year":"1998","journal-title":"Science."},{"key":"2020021219322999800_B13","doi-asserted-by":"crossref","first-page":"13399","DOI":"10.1074\/jbc.274.19.13399","article-title":"Inhibition of spontaneous receptor phosphorylation by residues in a putative \u03b1-helix in the KIT intracellular juxtamembrane region.","volume":"274","author":"Ma","year":"1999","journal-title":"J Biol Chem."},{"key":"2020021219322999800_B14","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0889-8588(05)70303-8","article-title":"A proposed classification for mastocytosis incorporating molecular genetics.","volume":"14","author":"Longley","year":"2000","journal-title":"Hematol Oncol Clin North Am."},{"key":"2020021219322999800_B15","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0889-8588(05)70302-6","article-title":"New approaches to therapy for mastocytosis: a case for treatment with kit kinase inhibitors.","volume":"14","author":"Longley","year":"2000","journal-title":"Hematol Oncol Clin North Am."},{"key":"2020021219322999800_B16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0145-2126(88)90050-1","article-title":"Establishment of an immature mast cell line from a patient with mast cell leukemia.","volume":"12","author":"Butterfield","year":"1988","journal-title":"Leuk Res."},{"key":"2020021219322999800_B17","first-page":"100","article-title":"Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.","volume":"56","author":"Buchdunger","year":"1996","journal-title":"Cancer Res."},{"key":"2020021219322999800_B18","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V96.3.925","article-title":"Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.","volume":"96","author":"Heinrich","year":"2000","journal-title":"Blood."},{"key":"2020021219322999800_B19","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.","volume":"293","author":"Gorre","year":"2001","journal-title":"Science."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/99\/5\/1741\/1681621\/h8050201741.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/99\/5\/1741\/1681621\/h8050201741.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T01:09:04Z","timestamp":1581556144000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/99\/5\/1741\/106999\/The-cKIT-mutation-causing-human-mastocytosis-is"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3,1]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,3,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.v99.5.1741","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2002,3,1]]}}}